Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 3/20 | 0.78 |
| ▸ | TDP2 | O95551 | 2/20 | 0.78 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.78 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.78 |
| ▸ | MITF | O75030 | 4/20 | 0.50 |
| ▸ | APAF1 | O14727 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 9/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | CCR6 | P51684 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046781 | 0.92 | NSD2 (0.64) | NSD2TDP2PLA2G1BATG4BMITF | |
| SCHEMBL29881618 | 0.92 | NSD2 (0.64) | NSD2TDP2PLA2G1BATG4BMITF | |
| SCHEMBL8651868 | 0.88 | NSD2 (1.00) | NSD2TDP2PLA2G1BATG4BMITF | |
| SCHEMBL20046775 | 0.82 | NSD2 (0.53) | NSD2TDP2PLA2G1BATG4BMITF | |
| SCHEMBL17249910 | 0.82 | NSD2 (0.88) | NSD2TDP2PLA2G1BATG4BMITF | |
| SCHEMBL20046757 | 0.82 | MAPT (0.67) | NSD2TDP2PLA2G1BATG4BMITF | |
| SCHEMBL17249924 | 0.78 | TDP2 (0.71) | NSD2TDP2PLA2G1BATG4BMITF | |
| SCHEMBL20046946 | 0.76 | IDO1 (0.58) | NSD2TDP2PLA2G1BATG4BMITF | |
| SCHEMBL29881216 | 0.75 | IDO1 (0.75) | NSD2TDP2PLA2G1BATG4BMITF | |
| SCHEMBL16745430 | 0.75 | IDO1 (0.75) | NSD2TDP2PLA2G1BATG4BMITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200283417-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-10 | — | — | US | disclosed |
| WO-2018067842-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283417-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | MCL1, NPM1, ABL1 | NSD2 327/4885TDP2 3309/4885PLA2G1B 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.